NCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
Clinical Trials
94 trialsNCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07446777 2026-03-03
FAST-M
University of Miami
Phase NA Not yet recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07429721 2026-02-24
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Not yet recruiting
NCT07082270 2026-02-19
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Not yet recruiting
NCT07382739 2026-02-17
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07409454 2026-02-13
CAREMM-007
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07407010 2026-02-12
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07403071 2026-02-11
Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting
NCT07234721 2026-02-10
SL4903
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07399444 2026-02-10
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT05874193 2026-02-05
COSTA
Duke University
Phase 2 Not yet recruiting
NCT07388147 2026-02-04
SAPPHIRE-MM
University Hospital Heidelberg
Phase NA Not yet recruiting
NCT07009899 2026-01-29
RECLAIM
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07376720 2026-01-29
A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
Tongji Hospital
Phase NA Not yet recruiting
NCT07376733 2026-01-29
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
Universidad Complutense de Madrid
Phase NA Not yet recruiting
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT07185490 2026-01-20
IASO104
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07312942 2026-01-20
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
Universidad Complutense de Madrid
Phase NA Not yet recruiting
NCT07353554 2026-01-20
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT07348393 2026-01-16
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Phase 2 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07236502 2026-01-12
MFM
Medical College of Wisconsin
Phase NA Not yet recruiting
NCT07322159 2026-01-07
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07319897 2026-01-06
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Peking University First Hospital
Phase 2/3 Not yet recruiting
NCT07276230 2025-12-29
ENTRAIDANT
Assistance Publique - Hôpitaux de Paris
Phase NA Not yet recruiting
NCT07292272 2025-12-26
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
University of Nebraska
Phase 2 Not yet recruiting
NCT07102212 2025-12-24
FOCUS
Ohio State University Comprehensive Cancer Center
Phase NA Not yet recruiting
NCT07289087 2025-12-17
QOL-ONE PRO-CT
Associazione Qol-one
Not yet recruiting
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07283224 2025-12-15
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Not yet recruiting
NCT07253103 2025-11-28
Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients
University of Salamanca
Phase NA Not yet recruiting
NCT07221032 2025-10-27
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07198958 2025-09-30
MITOX
IRCCS San Raffaele
Not yet recruiting
NCT07200089 2025-09-30
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07191379 2025-09-24
SCILLA
Odense University Hospital
Phase 4 Not yet recruiting
NCT06698744 2025-09-23
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07185477 2025-09-22
QLS32015
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07045168 2025-09-15
Risk-adapted Therapeutic Strategy in +1q NDMM
The First Hospital of Jilin University
Not yet recruiting
NCT07113496 2025-08-13
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Not yet recruiting
NCT07114432 2025-08-11
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Not yet recruiting
NCT06580223 2025-07-18
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT07070934 2025-07-17
ASCTvsCAR-T
Xuzhou Medical University
Phase 2 Not yet recruiting
NCT07070960 2025-07-17
CAR-T
Xuzhou Medical University
Phase NA Not yet recruiting
NCT07034755 2025-07-02
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
The Affiliated Hospital of Xuzhou Medical University
Phase NA Not yet recruiting